Literature DB >> 18940267

Antihypertensive, antioxidant, antidyslipidemic and endothelial modulating activities of a polyherbal formulation (POL-10).

Nauman Aziz1, Malik Hassan Mehmood, Safur Rehman Mandukhal, Samra Bashir, Sidra Raoof, Anwarul Hassan Gilani.   

Abstract

The present investigation was aimed at providing the pharmacological basis for the medicinal use of a polyherbal formulation (POL-10) in hypertension and dyslipidemia. In spontaneously hypertensive rats, POL-10 significantly (p<0.05) reduced blood pressure to 183.2+/-2.97 vs 198.1+/-5.2 mmHg (Mean+/-S.E.M; n=7-10), improved endothelial dysfunction (p<0.01) by increasing acetylcholine-induced relaxation up to 46.0+/-6.7% vs 24.6+/-3.8% (n=5-10) and decreased serum triglycerides (TG) to 54.5+/-3.3 vs. 93.84+/-5.7 mg/dl (p<0.001). In high fat diet-induced hypercholesterolemia, POL-10 caused reduction in total cholesterol (TC), low density lipoproteins (LDL) levels and the atherogic index (TC-HDL/HDL). It decreased TG levels in tyloxapol-induced hyperlipidemia and increased high-density lipoprotein cholesterol (HDL-C) and reduced atherogenic index in normotensive rats. It exhibited strong antioxidant activity in different in vitro assays. In isolated smooth muscle preparation, POL-10 exhibited calcium channel blocking (CCB) activity by inhibition of high K(+)- induced contractions and rightward shift of Ca(++) concentration-response curves similar to that of verapamil. In conclusion, these findings rationalize the medicinal use of POL-10 in cardiovascular disorders which are mediated through multiple pathways such as, antioxidant, CCB, inhibition of lipid biosynthesis and absorption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940267     DOI: 10.1016/j.vph.2008.09.003

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  8 in total

1.  Studies on antidyslipidemic effects of Morinda citrifolia (Noni) fruit, leaves and root extracts.

Authors:  Saf-ur Rehman Mandukhail; Nauman Aziz; Anwarul-Hassan Gilani
Journal:  Lipids Health Dis       Date:  2010-08-20       Impact factor: 3.876

2.  The characteristics of dyslipidemia patients with different durations in Beijing: a cross-sectional study.

Authors:  Yingying Liu; Puhong Zhang; Wei Wang; Huan Wang; Ling Zhang; Wei Wu; Xiuhua Guo
Journal:  Lipids Health Dis       Date:  2010-10-13       Impact factor: 3.876

3.  Physiological properties of beetroot crisps applied in standard and dyslipidaemic diets of rats.

Authors:  Monika Wroblewska; Jerzy Juskiewicz; Wieslaw Wiczkowski
Journal:  Lipids Health Dis       Date:  2011-10-14       Impact factor: 3.876

4.  Cardiac and Vascular Synergic Protective Effect of Olea europea L. Leaves and Hibiscus sabdariffa L. Flower Extracts.

Authors:  Matteo Micucci; Marco Malaguti; Tullia Gallina Toschi; Giuseppe Di Lecce; Rita Aldini; Andrea Angeletti; Alberto Chiarini; Roberta Budriesi; Silvana Hrelia
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

5.  Cholesterol-cholate-butterfat diet offers multi-organ dysfunction in rats.

Authors:  Humaira Jamshed; Jamshed Arslan; Anwar-ul-Hassan Gilani
Journal:  Lipids Health Dis       Date:  2014-12-16       Impact factor: 3.876

6.  Pharmacological basis for the medicinal use of polyherbal formulation and its ingredients in cardiovascular disorders using rodents.

Authors:  Abdul Malik; Malik Hassan Mehmood; Hajra Channa; Muhammad Shoaib Akhtar; Anwarul-Hassan Gilani
Journal:  BMC Complement Altern Med       Date:  2017-03-07       Impact factor: 3.659

7.  Calcium antagonistic activity of Bacopa monniera in guinea-pig trachea.

Authors:  Shabana Channa; Ahsana Dar
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

8.  Studies on two polyherbal formulations (ZPTO and ZTO) for comparison of their antidyslipidemic, antihypertensive and endothelial modulating activities.

Authors:  Nauman Aziz; Malik Hassan Mehmood; Anwarul-Hassan Gilani
Journal:  BMC Complement Altern Med       Date:  2013-12-26       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.